Loading
Life sciences · Journal article
Acs Pharmacology & Translational Science · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Human-associated gut bacteria harbor diverse genetic and metabolic potential. Orally administered therapeutic drugs can interact with these bacteria in the gastrointestinal tract. Recent evidence shows modifications of multiple drugs via gut bacteria, influencing therapeutic outcomes. Trifluridine, a fluoropyrimidine drug used in colorectal cancer treatment, is susceptible to microbial metabolism and premature inactivation, yet the breadth and functional consequences of this metabolism remain incompletely defined. In this work, we further explore the potential of additional gut bacterial strains that can metabolize trifluridine and characterize how this microbial metabolism impacts cancer cell responses. Sequence-based similarity search revealed trifluridine metabolizing homologues in multiple Enterobacteriaceae species including Klebsiella oxytoca. LCMS analysis confirms that gut isolates, Escherichia coli NS-12 and K. oxytoca S-22, efficiently degraded TF within 2 h. Tipiracil, the clinical inhibitor of host thymidine phosphorylase, only partially blocked microbial TF metabolism dependent on oxygen availability and the bacterial strain. Functionally, the treatment efficacy of TF was reduced, and it lost its cytotoxic potential in cancer when pre-exposed to E. coli and K. oxytoca. Also, microbially degraded TF could not induce the oncogenic p53-dependent pathways in cancer cells compared to the intact TF drug. These findings demonstrate that microbial TF metabolism is widespread across the gut bacteria and can directly undermine its anticancer efficacy and highlight the need to consider gut microbial composition when optimizing TF-based cancer therapies.